Oncorus (OTCPK:ONCR) - Aandelenkoers, Nieuws & Analyse

ONCR Overzicht aandelen

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. Meer informatie

ONCR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 25.8% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $3M )

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 1 meer risico

Oncorus, Inc. Concurrenten

Tharimmune

NasdaqCM:THAR

US$3.9m

Bio-Path Holdings

NasdaqCM:BPTH

US$3.4m

Oncternal Therapeutics

NasdaqCM:ONCT

US$3.4m

Matinas BioPharma Holdings

NYSEAM:MTNB

US$2.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Oncorus
Historische aandelenkoersen
Huidige aandelenkoers	US$0.13
52 Week Hoogtepunt	US$0.47
52 Week Laag	US$0.01
Bèta	1.95
11 maand verandering	500.00%
3 maanden verandering	427.20%
1 Jaar Verandering	-58.00%
33 jaar verandering	-99.63%
5 jaar verandering	n/a
Verandering sinds IPO	-99.21%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ONCR	US Biotechs	US Markt
7D	26.0%	2.4%	2.2%
1Y	-58.0%	16.2%	31.7%

Rendement versus industrie: ONCR presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.2 % opleverde.

Rendement versus markt: ONCR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is ONCR's price volatile compared to industry and market?
ONCR volatility
ONCR Average Weekly Movement	210.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ONCR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ONCR is het afgelopen jaar gestegen van 101% naar 210%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	64	Craig Jalbert	www.oncorus.com

Oncorus, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Oncorus zich tot de beurswaarde?
ONCR fundamentele statistieken
Marktkapitalisatie	US$3.29m
Inkomsten(TTM)	-US$90.54m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is ONCR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ONCR resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$90.54m
Inkomsten	-US$90.54m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.47
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	66.0%

Hoe presteerde ONCR op de lange termijn?

Bekijk historische prestaties en vergelijking

ONCR Overzicht aandelen

Risicoanalyse

Oncorus, Inc. Concurrenten

NasdaqCM:THAR

US$3.9m

NasdaqCM:BPTH

US$3.4m

NasdaqCM:ONCT

US$3.4m

NYSEAM:MTNB

US$2.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus Appoints Scott Canute to Its Board of Directors

Oncorus reports Q3 results

Oncorus, Inc. has filed an IPO in the amount of $86.25 million.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Oncorus, Inc. Samenvatting

0.0x

0.0x

Inkomsten en omzet